Federico Rojo

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

Arkaitz Carracedo, Li Ma, Julie Teruya‐Feldstein et al. · Journal of Clinical Investigation · 2008 · 1.4K citations · Full text

Medicine, Oncology, Pharmacology +17

Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer

Maurizio Scaltriti, Federico Rojo, Alberto Ocaña et al. · JNCI Journal of the National Cancer Institute · 2007 · 881 citations · Full text

Medicine, Cancer Biology, Oncology +17

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types

José Baselga, Danny Rischin, Malcolm Ranson et al. · Journal of Clinical Oncology · 2002 · 831 citations

Medicine, Oncology, Pharmacology +16

PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization

Incheol Shin, F. Michael Yakes, Federico Rojo et al. · Nature Medicine · 2002 · 786 citations

Life Sciences, Cell Biology, Molecular Biology +16

Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.

Jordi Codony‐Servat, Joan Albanell, Federico Rojo et al. · PubMed · 2001 · 775 citations

Medicine, Molecular Biology, Oncology +16